Bamboos Health Care Holdings Ltd (2293) AI Stock Analysis

• Market Cap: HK$229.40M
• Dividend Yield: 13.39%
• Average Volume (3M): 153.09K
• Price to Earnings (P/E): 9.6
• Beta (1Y): 0.06
• Revenue Growth: -22.12%
• EPS Growth: -28.95%
• Country: HK
• Employees: 75
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Care Facilities
• EPS (TTM): 0.03
• Shares Outstanding: 402,460,000
• 10 Day Avg. Volume: 124,800
• 30 Day Avg. Volume: 153,095
• PEG Ratio: -0.40
• Price to Book (P/B): 0.99
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 12.57
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: HK$0.50 ▼(-12.28%Downside)

Bamboos Health Care Holdings Ltd scores well in financial performance due to strong profitability and liquidity, despite revenue declines. The stock appears fairly valued with an attractive dividend yield. However, technical indicators signal overbought conditions, which may pose short-term risks.

Bamboos Health Care Holdings Ltd Business Overview & Revenue Model

Company Description

Bamboos Health Care Holdings Limited, an investment holding company, provides healthcare staffing solutions in Hong Kong. It offers healthcare institution support and private nursing solutions. The company also provides marketing and consulting services; and technology promotion and application services, as well as operates aesthetic clinics. It serves individuals and institutional clients, including hospitals, social service organizations, and clinics. The company was founded in 2009 and is headquartered in Tsim Sha Tsui, Hong Kong.

How the Company Makes Money

Bamboos Health Care Holdings Ltd generates revenue through its staffing services by charging fees for the placement of healthcare professionals. The company earns money by contracting with healthcare facilities that require temporary or permanent staffing solutions. These facilities pay Bamboos a fee for sourcing, vetting, and providing qualified healthcare personnel. The company may also generate additional revenue from training and consultancy services offered to both healthcare professionals and institutions, enhancing the skill set and operational efficiencies within the healthcare industry.

Bamboos Health Care Holdings Ltd Financial Statement Overview

Summary

Bamboos Health Care Holdings Ltd demonstrates strong profitability and efficient operations with high margins and a solid balance sheet. However, declining revenues over recent years raise concerns about future growth prospects. The company maintains a strong liquidity position, supporting its operations despite revenue challenges.

Income Statement

The company shows strong gross and net profit margins with a Gross Profit Margin of 89.4% and a Net Profit Margin of 32.6% for the latest period. However, the revenue has decreased significantly over the past few years, with a noticeable decline of 25.8% from 2022 to 2023 and another decline of 25.8% from 2023 to 2024. EBITDA and EBIT margins remain robust, indicating efficient cost management.

Balance Sheet

The company maintains a strong equity position with an Equity Ratio of 68.6%. The Debt-to-Equity Ratio is low at 0.29, indicating conservative leverage. However, the Return on Equity has decreased over the period, reflecting the decline in net income relative to equity. The company has maintained strong liquidity with substantial cash reserves.

Cash Flow

Free Cash Flow remains positive, although it decreased by 14.2% from 2023 to 2024. The Operating Cash Flow to Net Income Ratio is robust, showing effective conversion of income to cash. The Free Cash Flow to Net Income Ratio also remains healthy, indicating good cash generation relative to net income.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	94.79M	127.81M	141.40M	110.80M	72.32M
Gross Profit	84.72M	77.66M	91.33M	82.19M	38.73M
EBITDA	52.76M	71.06M	81.32M	78.05M	42.71M
Net Income	30.92M	46.92M	58.62M	61.02M	30.69M
Balance Sheet
Total Assets	318.06M	346.83M	351.35M	240.84M	181.88M
Cash, Cash Equivalents and Short-Term Investments	81.15M	103.97M	93.83M	106.17M	101.63M
Total Debt	63.73M	68.24M	68.96M	3.31M	5.76M
Total Liabilities	99.74M	124.51M	140.75M	46.05M	28.61M
Stockholders Equity	218.33M	222.32M	210.60M	194.79M	153.27M
Cash Flow
Free Cash Flow	35.75M	41.67M	100.37M	49.42M	42.90M
Operating Cash Flow	37.41M	41.94M	116.11M	49.44M	45.52M
Investing Cash Flow	-7.09M	6.92M	-111.63M	-71.38M	-29.71M
Financing Cash Flow	-42.44M	-41.80M	25.15M	-23.04M	-32.87M

Bamboos Health Care Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.57
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2293, the sentiment is Positive. The current price of 0.57 is above the 20-day moving average (MA) of 0.52, above the 50-day MA of 0.52, and below the 200-day MA of 0.59, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 67.97 is Neutral, neither overbought nor oversold. The STOCH value of 84.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2293.

Bamboos Health Care Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0722	78 Outperform	HK$400.47M	9.31	5.95%	9.49%	0.81%	27.55%
2293	64 Neutral	HK$229.40M	9.60	10.72%	13.39%	-22.12%	-28.95%
8307	60 Neutral	HK$73.79M	―	-44.60%	―	-8.20%	-10.39%
8357	60 Neutral	HK$98.59M	―	-1.41%	―	-13.38%	78.75%
1419	56 Neutral	HK$326.41M	15.55	2.73%	3.26%	-0.69%	―
Sector *	52 Neutral	$7.46B	-0.04	-63.82%	2.49%	16.43%	<0.01%
8143	51 Neutral	HK$140.91M	―	-18.22%	―	-56.16%	62.50%

Bamboos Health Care Holdings Ltd Corporate Events

Bamboos Health Care Holdings Ltd Establishes Nomination Committee

Bamboos Health Care Holdings Limited has announced the establishment of a Nomination Committee, effective from June 30, 2025. This committee, primarily composed of independent non-executive directors, aims to enhance governance by overseeing nominations and appointments within the company. The move is expected to strengthen the company’s operational framework and align with best practices in corporate governance.

Bamboos Health Care Announces Share Awards to Boost Employee Retention

Bamboos Health Care Holdings Ltd has released a supplemental announcement to its 2024 Annual Report, detailing the activities of its Remuneration Committee. The committee has granted 2,460,000 share awards to 21 employees, aligning with the company’s goals to reward contributions and retain talent for ongoing development. This move is expected to enhance the company’s operational continuity and align employee interests with those of the shareholders.

Bamboos Health Care Strengthens Compliance with Remedial Measures

Bamboos Health Care Holdings Ltd has implemented remedial measures to ensure compliance with the Listing Rules, specifically regarding the timely publication of announcements for discloseable transactions. As part of these measures, the company’s responsible staff have completed a certified course on notifiable transactions provided by The Hong Kong Chartered Governance Institute, demonstrating the company’s commitment to regulatory adherence and enhancing its governance practices.

Bamboos Health Care Holdings Faces Delay in Transaction Disclosure

Bamboos Health Care Holdings Ltd, a company incorporated in the Cayman Islands, announced a delay in the publication of a discloseable transaction related to the acquisition of shares in SPDR Gold Trust. The delay was due to internal control deficiencies and personnel changes, which resulted in a breach of the Listing Rules. The company failed to ensure proper handover procedures and training for new staff, impacting compliance with the rules regarding the calculation of size tests and transaction aggregation.